Driving reinvestment in R&D for antibiotics and advocating their responsible use

WP3A: Project management and governance

LEADER
Academic: Stephan Harbarth, University of Geneva, Switzerland
EFPIA: Judy Hackett, Astra Zeneca AB

PARTNERS
E. Bettiol, S. Legros, F. Jantarada (University of Geneva)

The private partners in DRIVE-AB are: AstraZeneca AB, GlaxoSmithKline Research & Development, F. Hoffmann-La Roche Ltd, MSD, Astellas Pharma Europe LTD, Pfizer Limited and Sanofi-Aventis Research & Development

OBJECTIVES

  1. Establish governance structure for the DRIVE-AB network.
  2. Coordinate the work packages and their collaboration, supporting the implementation of any changes in activities or the network.
  3. Ensure and assist in day-to-day operational management, providing administrative and logistic support to the work packages and Steering Committee.
  4. Ensure adherence to the project agreement, monitoring the effective execution of tasks and timely achievement of project deliverables and milestones.
  5. Provide financial management of the network, with oversight of resource usage and payment.
  6. Protect and monitor intellectual property.

DOWNLOADS & RESOURCES

For more detail about Package 3A progress, please see our past NEWSLETTERS.

OUTPUTS

Article: Antibiotic research and development: business as usual?